Meltwind
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Qureight is an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials, with a focus on lung and heart disease. Deep learning models built on 3D chest imaging quantify structural changes that indicate disease progression, giving biopharma partners measurable endpoints during trials.
IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
IMU Biosciences is a biotechnology company that uses a simple blood sample to measure over 100 million immune data points by combining high-fidelity multi-omic analysis with proprietary machine learning analytics. The platform is designed to enable disease diagnosis, monitor treatment progression, and predict treatment suitability for individual patients.
Enhanced Genomics raises £14m Series A from investors to advance therapeutics pipeline with its 3D multi-omics platform
Enhanced Genomics uses a three-dimensional multi-omics platform to identify genetically validated drug targets, supporting the development of new medicines for complex common diseases.
- 3(12 months)
- meltwind.co.uk
- Update Information
More venture news
- 3 Aug 2026
OlixOLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production
Series BDeep Tech - 5 Aug 2026
MironidMironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences - 29 Jul 2026
GreyparrotGreyparrot raises £20m Series B from angels for AI camera systems that read waste on recycling belts
Series BClimate